This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Health Discovery Corporation (OTCBB: HDVY) is pleased to announce that the United States Patent and Trademark Office has issued the first of what the Company expects to be several patents covering methods to screen for the presence of prostate cancer using genomic biomarkers that were identified by HDC researchers using the Company's patented RFE-SVM algorithm. The genomic biomarkers covered by the claims of HDC's Patent No. 8,008,012 each performs well individually to distinguish prostate cancer from non-cancer (normal and BPH), however, the unique combination of the genomic biomarkers comprising this HDC prostate cancer test produced an overall test accuracy of 89%. By comparison, the PCA3 test for prostate cancer, developed by Gen-Probe Incorporated and commercially on sale in the United States and Europe, has been reported as having an overall test accuracy of around 81%, while overall test accuracy for PSA is only about 47%.
With the issuance of the new patent, HDC now holds exclusive rights to a total of 55 issued U.S. and foreign patents. HDC has a total of 88 patents pending and issued.
"HDC is very pleased to receive notice from the United States Patent and Trademark Office that the first of several HDC prostate biomarker patents has now been approved and issued," stated Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "HDC remains firmly committed to successfully monetizing our valuable intellectual property through additional licensing, close collaboration, development and commercialization with our business partners, and we will also continue to protect our patent portfolio through robust enforcement action when strategically appropriate."
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relating to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop or commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.